Mölnlycke and Zuellig Pharma have announced a new partnership that will focus on providing more advanced wound care products and solutions to patients and healthcare practitioners across South-East Asia. This strategic partnership follows Mölnlycke’s successful acquisition of SastoMed in July 2018, augmenting Mölnlycke’s range of wound care solutions with SastoMed’s ground-breaking, oxygen-therapy based solutions for chronic wounds (via its products Granulox and Granudacyn).
The commercialisation of Granulox and Granudacyn in South-East Asia was previously managed by SastoMed’s exclusive strategic partner, Zuellig Pharma, one of Asia’s largest healthcare services provider.
The new partnership will reflect Mölnlycke’s extensive experience in the marketing, medical and sales management of their advanced wound care portfolio (including Granulox and Granudaycn) while leveraging on Zuellig Pharma’s extensive network to ensure that their products become more assessible to the communities across Asia.
‘We are pleased to continue working with our long-standing partner Zuellig Pharma. Adding oxygen therapy to our leading range of healing solutions for chronic wounds is a fundamental milestone for Mölnlycke in advancing wound care in this progressive and rapidly developing region,’ says Richard Twomey, CEO of Mölnlycke.
‘Zuellig Pharma is in a strong position to support growing healthcare needs in the region. This new strategic partnership with Mölnlycke is testament to the confidence our partners have in the work we do and will tap on the deep networks and capabilities we have established across the region to make healthcare more accessible in the communities we serve,’ said John Graham, Senior Vice-President Commercial Solutions, Zuellig Pharma.
The partnership will roll out in specific countries in South-East Asia, expanding to more markets over time.